Evimatic® is an AI-based information system designed to answer questions about the efficacy, safety, and benefit-risk ratio of ADHD treatments. It employs clinical practice guideline methodologies in a manner that is automated, personalized, participatory, and accessible from the user’s location. This capability is made possible by APPRAISE-RS, an AI system that adapts the GRADE methodology for developing clinical practice guidelines. APPRAISE-RS facilitates an updated, personalized, and participatory analysis of evidence. Moreover, Evimatic® provides explanations of its analyses that are understandable to anyone with basic knowledge of evidence-based medicine.
APPRAISE-RS employs an AI heuristic recently validated through an in silico model (i.e., with simulated data). This model can be downloaded by clicking the image provided below.
Currently, the APPRAISE-RS recommendation system is being validated with ADHD patients in two clinical studies (NCT04228094 and NCT05651685).
